Most Recent Articles by Brian Ellis
Updates to the US Preventive Services Task Force's recommendations on obesity screening in children and adolescents focus on intensive behavioral interventions.
Semaglutide significantly increased insulin response and was well-tolerated in patients with type 2 diabetes.
There were no significant differences in hemoglobin A1c across the 3 self-monitoring blood glucose groups.
More patients in the device-supported group achieved a fasting self-monitored plasma glucose target of 90 to 130 mg/dL at week 16 without severe hypoglycemia.
HbA1c fell from 7.9%±2.0% at admission to 7.1%±1.5% at 3 months after discharge.
More Articles by Brian Ellis
Endocrinology Advisor Articles
- Semaglutide Improved Beta-Cell Function and Glycemic Control in Type 2 Diabetes
- Blood Glucose Self-Monitoring in Type 2 Diabetes Does Not Benefit Glycemic Control
- Elagolix Relieves Short-Term Menstrual Pain, Dysmenorrhea in Endometriosis
- Improving Glycemic Control in T2D With Text Message Intervention
- The Handoff: Your Week in Endocrinology News - 6/23/17
- Reduced Cardiovascular Events in Type 2 Diabetes Treated With Dapagliflozin
- Prolonged Delayed Eating Linked to Weight Gain, Increased Respiratory Quotient
- Canagliflozin Reduces Cardiovascular Stress In Older Patients With Type 2 Diabetes
- GLP-1 Analog Counteracts Antipsychotic-Induced Glucose Intolerance, Weight Gain
- Diabetic Retinopathy Caused by Sleep Apnea in T2D
- USPSTF Updates Recommendations for Screening Obesity in Children and Adolescents
- Exercise Protocol Improves Outcomes in T2D
- Interspersed Upper Body Activity With Sedentary Time Improves Glucose, Insulin
- AHA Advisory: Replace Saturated Fat to Reduce CVD By 30%
- Type 2 Diabetes Death and CV Events Predicted by Systolic Blood Pressure Variability